Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Results reported from phase III Japanese studies of KRN-125

Jan. 25, 2013

Curis doses first patient in phase I trial of CUDC-907

Jan. 25, 2013

Lupin presents new PKM2 activators

Jan. 25, 2013

Researchers at Tempero Pharmaceuticals design new HDAC9 inhibitors

Jan. 25, 2013

New inhibitors of pim-1, pim-2 and/or pim-3 presented by CNIO

Jan. 25, 2013

New acid ceramidase inhibitors patented by CSIC and the Universitat de Barcelona

Jan. 25, 2013

Sorafenib tested in patients with esophageal and gastroesophageal junction cancer

Jan. 25, 2013

Astex Pharmaceuticals presents phase I results for AT-13387 in GIST

Jan. 25, 2013

Vismodegib + FOLFOX evaluated in gastroesophageal carcinoma

Jan. 25, 2013

New antitumor agents disclosed at Novartis

Jan. 24, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 10, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...